The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.
Scientists from Oxford's Radcliffe Department of Medicine have achieved the most detailed view yet of how DNA folds and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback